Hennigsdorf/Berlin (Germany), December 13, 2023 – Adrenomed AG, the vascular integrity company, today announced its participation in upcoming industry and investor conferences. The Adrenomed management team will be available for meetings to present the plans for its global phase 2 confirmatory study in septic shock and discuss partnering opportunities:
42nd Annual J.P. Morgan Healthcare Conference (link)
January 8 – 11, 2024, San Francisco, CA, USA
Dr. Richard Jones, CEO of Adrenomed, and David Germonpré, CFO, will be available onsite and throughout the entire week for networking, partnering and one-on-one discussions.
Biotech Showcase™ (link)
January 8 – 10, 2024, San Francisco, CA, USA
January 16 – 17, 2024, virtual partnering
Dr. Richard Jones, CEO, and David Germonpré, CFO, will be available for 1:1 partnering in San Francisco and for virtual meetings the following week, and can be accessed through partneringONE®.
About Adrenomed
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate enibarcimab (formerly adrecizumab) is a first-in-class non-blocking monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.
Contact
Adrenomed AG
Martina Kalle-Brune, Ph.D.
phone: +49 (0)3302 207780
bd@adrenomed.com
Media Inquiries
MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu
